Market Place
Sourcing Support
Legend Biotech to Present at 43rd J.P. Morgan Healthcare Conference
19 Dec 2024 //
GLOBENEWSWIRE
Carvykti Show Improved MRD Negativity in Relapsed Multiple Myeloma
09 Dec 2024 //
GLOBENEWSWIRE
Legend Biotech Reports Q3 2024 Results and Recent Highlights
12 Nov 2024 //
GLOBENEWSWIRE
Legend Biotech to Host Event at ASH 2024 Annual Meeting
07 Nov 2024 //
GLOBENEWSWIRE
Legend Biotech Unveils MRD Data from CARTITUDE-4 Myeloma Trial
05 Nov 2024 //
GLOBENEWSWIRE
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
04 Nov 2024 //
GLOBENEWSWIRE
Legend Biotech To Host Q3 2024 Investor Conference Call
24 Oct 2024 //
GLOBENEWSWIRE
Legend sheds Genscript as its majority shareholder
23 Oct 2024 //
FIERCE PHARMA
Legend set to open Philadelphia cell therapy R&D site next year
04 Oct 2024 //
FIERCE PHARMA
J&J, Legend`s Carvykti shows 45% survival benefit in myeloma
01 Oct 2024 //
FIERCE PHARMA
CARVYKTI Extends Survival Compared To Standard Myeloma Care
27 Sep 2024 //
GLOBENEWSWIRE
Legend strikes cell therapy automation pact with Multiply Labs
24 Sep 2024 //
FIERCE PHARMA
GenScript`s Legend Biotech Gets Cilta-cel Approval In China For Multiple Myeloma
27 Aug 2024 //
PR NEWSWIRE
Legend Biotech To Attend Morgan Stanley Healthcare Conference
20 Aug 2024 //
GLOBENEWSWIRE
Legend Biotech CEO takes ‘close look at business’ amid geopolitical risk
09 Aug 2024 //
FIERCE PHARMA
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
08 Aug 2024 //
GLOBENEWSWIRE
Legend Biotech Announces Preliminary Results For H1 2024
26 Jul 2024 //
GLOBENEWSWIRE
J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer
16 Jul 2024 //
FIERCE PHARMA
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
10 Jul 2024 //
GLOBENEWSWIRE
J&J, Legend`s Carvykti extends lives in multiple myeloma trial
03 Jul 2024 //
PRESS RELEASE
Legend Biotech Reports Positive OS Results From CARTITUDE-4 Trial
02 Jul 2024 //
GLOBENEWSWIRE
Lawmakers request briefing on CDMO GenScript, Legend Biotech
04 Jun 2024 //
FIERCE PHARMA
Legend`s CARVYKTI Early Use, Subgroup Data In Multiple Myeloma
03 Jun 2024 //
BUSINESSWIRE
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Legend Car-T Multiple Myeloma: Leadership Highlighted Asco Eha Featured
23 May 2024 //
BUSINESSWIRE
MaxCyte, Legend Bio Partner To Accelerate Cell Therapies
22 May 2024 //
GLOBENEWSWIRE
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
13 May 2024 //
BUSINESSWIRE
CARVYKTI Approved In EU For 2L Relapsed/Refractory Myeloma
22 Apr 2024 //
BUSINESSWIRE
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
11 Apr 2024 //
BUSINESSWIRE
Legend Biotech’s CARVYKTI Approved by the FDA for Second-Line Treatment of MM
05 Apr 2024 //
BUSINESSWIRE
U.S. FDA approves expanded use of J&J`s cancer cell therapy
05 Apr 2024 //
REUTERS
Legend, J&J tap Novartis for commercial production of Carvykti
29 Mar 2024 //
FIERCE PHARMA
Legend Biotech Announces Publication of Inaugural Environmental, (ESG) Report
19 Mar 2024 //
BUSINESSWIRE
CARVYKTI Receives Recommendation from FDA Oncologic Drugs Advisory Committee
15 Mar 2024 //
BUSINESSWIRE
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results
11 Mar 2024 //
BUSINESSWIRE
Legend CEO offers preview of high-stakes FDA adcomm for Carvykti
11 Mar 2024 //
FIERCE PHARMA
EMA recommends approval of Carvykti in earlier lines of multiple myeloma
24 Feb 2024 //
ENDPTS
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI
23 Feb 2024 //
BUSINESSWIRE
Legend Biotech to Host Conference on Fourth Quarter and Full Year 2023 Results
13 Feb 2024 //
BUSINESSWIRE
FDA calls external review of J&J, Legend`s Carvykti
23 Jan 2024 //
FIERCE PHARMA
GenScript, GenScript Pro, and Legend Biotech Will Attend the 42nd JPM Conference
04 Jan 2024 //
PR NEWSWIRE
Legend Biotech Announces Closing of License Transaction for CAR-T Therapies
03 Jan 2024 //
BUSINESSWIRE
Legend Bio to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Agency adds warning on secondary cancers for Carvykti
26 Dec 2023 //
ENDPTS
FDA adds Carvykti`s secondary cancer risk to boxed warning
21 Dec 2023 //
FIERCE PHARMA
Study Showed Meaningful Improvements Following Treatment with CARVYKTI
11 Dec 2023 //
BUSINESSWIRE
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
20 Nov 2023 //
BUSINESSWIRE
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront
14 Nov 2023 //
FIERCE BIOTECH
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment
02 Nov 2023 //
BUSINESSWIRE
Positive Outlook On Johnson & Johnson`s Partner Legend Biotech
18 Oct 2023 //
BENZINGA
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
13 Sep 2023 //
PRESS RELEASE
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
15 Aug 2023 //
PRESS RELEASE
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
03 Aug 2023 //
BUSINESSWIRE
Legend Biotech shares gain on multiple-myeloma drug sales
20 Jul 2023 //
MORNING STAR
Legend Biotech up 7% on strong Carvykti Q2 sales
20 Jul 2023 //
SEEKING ALPHA
Legend Biotech Announces Submission of Supplemental Application for CARVYKTI
06 Jun 2023 //
PRESS RELEASE
Cilta-cel Reduced Risk of Disease Progression in CARTITUDE-4 Study
05 Jun 2023 //
BUSINESSWIRE
Legend Biotech Announces Participation in Upcoming Investor Conferences
02 Jun 2023 //
BUSINESSWIRE
Legend Biotech Announces Submission to the EMA for Expanded Use of CARVYKTI
25 May 2023 //
BUSINESSWIRE
